Beijing, China, 20 July 2021 — Shanghai MicroPort® NeuroTech Co., Ltd. (MicroPort® NeuroTech) recently held a national launch of the Rapamycin Target Eluting Vertebral Stent System and Intracranial Support Catheter System at the 7th Annual Academic Conference of the Chinese Stroke Association and Tiantan International Stroke Conference (CSA&TISC 2021). The conference, held at the China National Convention Center in Beijing, brought together experts and scholars in the field of stroke prevention and control from all over the world to share academic research results, the latest advances and topical issues in cerebrovascular diseases.
The Bridge® Rapamycin Target Eluting Vertebral Stent System (Bridge® Stent System) features a unique drug delivery design in which the drug is only loaded inside the grooves on the stent surface facing the vessel wall, allowing for faster endothelialization and reduced thromboembolic events and restenosis. The U-track® Intracranial Support Catheter System (U-track® Catheter System) features a larger lumen compatible for the delivery of multiple system devices, thereby ensuring outstanding support, pushability and buckling resistance.
According to the clinical results of a long-term follow-up of vertebral artery stents shared by Professor Wei Wu from Qilu Hospital of Shandong University, the five-year restenosis rate (lesion level) of the Bridge® Stent System for vertebral artery stenosis is 7.1%; the rate of death or stroke related to the treatment of the target vessel supply area was 2.4%; and the rate of device-related SAEs was 1% during the five-year postoperative follow-up period. The Bridge® Stent System has demonstrated long-term effectiveness and safety for treatments of vertebral artery stenosis and is designed to meet the needs of clinical applications.
Guest lecturer at the event, Professor Dong Kuai, from Shanxi Cardiovascular Hospital, provided a summary of treatment approaches for vertebral artery stenosis lesions and fully recognized the safety and effectiveness of the Bridge® Stent System. According to Professor Kuai, research data shows that drug delivery stents reduce long-term restenosis rates, symptom recurrence rates and retreatment rates, and the Bridge® Stent System brings new hope for the treatment of ostial vertebral stenosis.
In addition, Professor Liangfu Zhu from Henan Provincial People’s Hospital pointed out that the standard use of intermediate catheters is one of the key factors in reducing complications in endovascular treatment of intracranial stenosis, treatment of non-acute intracranial artery occlusion, and endovascular treatment of acute ischemic stroke. Professor Zhu demonstrated the deliverability, support, precision and compatibility of the U-track® Catheter System by sharing case reports based on the clinical experience of the Stroke Center of Henan Provincial People’s Hospital.
Zhiyong Xie, President of MicroPort® NeuroTech, said, "The neurointerventional industry is developing by leaps and bounds. The launch of the Bridge® Rapamycin Target Eluting Vertebral Stent System and the U-track® Intracranial Support Catheter System brings more comprehensive treatment options for patients with vertebral artery stenosis and provides doctors with more available options. MicroPort® NeuroTech is committed to working towards providing accessible and exceptional medical solutions for stroke treatment through ongoing innovative research and development.”
About MicroPort® NeuroTech
MicroPort NeuroTech Co., Ltd. (MicroPort® NeuroTech) is a subsidiary of MicroPort Scientific Corporation (00853.HK). Founded in 2012, MicroPort® NeuroTech is a high-end medical device company focused on neuro-intervention and provides a full range of neuro-interventional products to treat brain disease.